公开(公告)号：US11457899B2

公开(公告)日：2022-10-04

申请号：US15515980

申请日：2015-09-30

Applicant: EXOSOME DIAGNOSTICS, INC.

Inventor： Johan Skog ,  Bill Tisel ,  Joseph Baker

IPC: A61B10/00 ,  A61B90/90 ,  B01L3/00

Abstract: In order to address an inability to separate portions of a sample and/or substance, in some embodiments, methods and apparatuses for separating components and/or portions of a sample are provided. For example, a sample collection container may comprise two areas within the container, one which is configured to contain a first volume of the sample, and one which is configured to contain a second volume of the sample. A float device may be configured to seal the portion of the container collecting the first volume from the portion of the container collecting the second volume, after the former portion of the container has been filled. The sample collection container may further comprise a top cap configured to further seal the two portions of the container, and to prevent leakage and/or spilling of the sample from the sample collection container.

公开(公告)号：US11345957B2

公开(公告)日：2022-05-31

申请号：US16631603

申请日：2018-07-18

Applicant: Exosome Diagnostics, Inc.

Inventor： Robert Kitchen ,  Michael Valentino ,  Johan Skog ,  Vasisht Tadigotla ,  Dalin Chan ,  Sudipto Chakrabortty ,  James Hurley

IPC: C12P19/34 ,  C12Q1/686 ,  C12Q1/6806 ,  C12Q1/6851 ,  C12Q1/6886

Abstract: The present disclosure relates to methods for treating glioblastoma in a subject in need thereof using gene signatures in exosomal RNA derived from the subject. The gene signatures comprise: at least one of FAM229B, ZNF35, CTD-2647L4.4, CABP5, CYP20A1, CEP126, DTX2P1-UPK3BP1-PMS2P11, RP11-507K12.1, KRBA2, CALD1, LRFN1, RP2, SLC2A13, CDKL3, SLC8A3, ANTXR2, TIGD5, AC074289.1 RP11-932O9.7; at least one of tRNA-Lys-CTT-2-2, tRNA-Pro-AGG-2-7, LAMTOR2, RAD51AP1, DENND2A, A1BG, THSD1, CSF1, RP11-332M2.1, ZNF717, ZNF860, ORC6, Clorf50, PSPH, HIST1H4C, CYP2U1, THAP8, TMEM192, NAA20; or at least one of CREBBP, CXCR2 and S100A9. The treatment methods comprise measuring the expression level of at least one of the aforementioned genes in exosomal RNA from a subject and administering to the subject a glioblastoma treatment based on the expression level(s).